|Bid||5.39 x 1300|
|Ask||5.73 x 1300|
|Day's Range||5.33 - 5.57|
|52 Week Range||4.14 - 11.52|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2021 - Nov 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.44|
Subscribe to Yahoo Finance Plus to view Fair Value for RDHLLearn more
Two new analyses evaluate pharmacological and clinical advantages of Talicia® as first-line H. pylori therapy over clarithromycin-based regimens-Two new analyses of Movantik® data evaluate efficacy in treating extreme opioid-induced constipation with severe symptoms-Talicia®, an FDA approved therapy, is designed to replace clarithromycin-based regimens as first-line H.
BioNTech (NASDAQ: BNTX) was up by 15.6% for the week as of the market close on Thursday, according to data from S&P Global Market Intelligence. Shares of Novavax (NASDAQ: NVAX), meanwhile, have lost 14.3%. BioNTech benefited from two positive developments.
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Adi Frish, RedHill's Chief Corporate & Business Development Officer, will present a corporate overview at the BIO-Europe Digital Conference, taking place October 25-28, 2021.